Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous tendon-derived progenitor cells
- Development stage
- Preclinical
- Lead developer
- University of Illinois
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intralesional
01
Overview
Autologous tendon-derived progenitor cells (TDPCs) are a specialized population of resident stem cells isolated from an individual's own tendon tissue and expanded *in vitro* for therapeutic use. These cells exhibit mesenchymal stem cell-like properties, including self-renewal and tenogenic differentiation potential. In clinical and veterinary research, particularly for treating equine flexor tendinitis, TDPCs are injected directly into tendon lesions to facilitate functional tissue repair. The therapeutic mechanism involves the cells' ability to organize the extracellular matrix, specifically by improving collagen fiber alignment and increasing the tensile strength of the repair tissue. Unlike natural healing, which often results in disorganized, weaker scar tissue, TDPC treatment aims to restore the biomechanical integrity of the tendon to levels comparable to healthy tissue.
- Other names
- autogenous tendon-derived progenitor cellstendon-derived progenitor cellstendon-derived stem cellsTDSCs
Beyond the preview
Go deeper on autologous tendon-derived progenitor cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous tendon-derived progenitor cells.